logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 15 of 15 Items
Showing 1 - 15 of 15 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Standards for clinical trials for treating TB

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C,  et al.
2023-12-01 • International Journal of Tuberculosis and Lung Disease
2023-12-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...
Journal Article
|
Research

Target product profiles: tests for tuberculosis treatment monitoring and optimization

Gupta-Wright A, den Boon S, MacLean E, Cirillo DM, Cobelens F,  et al.
2023-11-01 • Bulletin of the World Health Organization
2023-11-01 • Bulletin of the World Health Organization
The World Health Organization has developed target product profiles containing minimum and optimum targets for key characteristics for tests for tuberculosis treatment monitoring and opt...
Journal Article
|
Review

Programmatic management of drug-resistant tuberculosis: an updated research agenda

Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F,  et al.
2016-05-25 • PLOS One
2016-05-25 • PLOS One
INTRODUCTION
There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains li...
Journal Article
|
Commentary

The need to capitalize on new recommendations: Stimulating Tuberculosis Diagnostic Research in Children

Brigden G
2012-08-01 • Pediatric Infectious Disease Journal
2012-08-01 • Pediatric Infectious Disease Journal
Journal Article
|
Editorial

Tuberculosis and antimicrobial resistance - new models of research and development needed

Brigden G, Castro JL, Ditiu L, Gray G, Hanna D,  et al.
2017-05-01 • Bulletin of the World Health Organization
2017-05-01 • Bulletin of the World Health Organization
Journal Article
|
Review

Getting it right for children: improving tuberculosis treatment access and new treatment options

Brigden G, Furin J, van Gulik C, Marais BJ
2015-03-05 • Expert Review of Anti-Infective Therapy
2015-03-05 • Expert Review of Anti-Infective Therapy
Children were often the forgotten victims of the global tuberculosis (TB) epidemic, neglected by traditional TB services as well as maternal and child health initiatives. Luckily this is...
Journal Article
|
Commentary

Barriers to New Drug Development in Respiratory Disease

Brigden G, du Cros PAK, Wong S
2016-01-01 • European Respiratory Journal
2016-01-01 • European Respiratory Journal
Journal Article
|
Letter

Resistance to second-line drugs in multidrug-resistant tuberculosis

Nyang'wa BT, Brigden G, du Cros PAK, Shanks L
2013-02-23 • Lancet
2013-02-23 • Lancet
Journal Article
|
Review

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid

Brigden G, Hewison CCH, Varaine FFV
2015-10-30 • Infection and Drug Resistance
2015-10-30 • Infection and Drug Resistance
Journal Article
|
Review

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement

Nachman S, Ahmed AO, Amanullah F, Becerra M, Botgros R,  et al.
2015-06-01 • Lancet Infectious Diseases
2015-06-01 • Lancet Infectious Diseases
Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available treatments for paediatric drug-susceptible and drug-resistant tuber...
Journal Article
|
Commentary

Principles for designing future regimens for multidrug-resistant tuberculosis

Brigden G, Nyang'wa BT, du Cros PAK, Varaine FFV, Hughes J,  et al.
2014-01-01 • Bulletin of the World Health Organization
2014-01-01 • Bulletin of the World Health Organization
Fewer than 20% of patients with multidrug-resistant (MDR) tuberculosis are receiving treatment and there is an urgent need to scale up treatment programmes. One of the biggest barriers t...
Journal Article
|
Commentary

Empiric tuberculosis treatment in retreatment patients in high HIV/tuberculosis-burden settings

Balasegaram M, Brigden G
2014-09-01 • Lancet Infectious Diseases
2014-09-01 • Lancet Infectious Diseases
Journal Article
|
Research

Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis

Cox V, Brigden G, Crespo RH, Lessem E, Lynch S,  et al.
2018-04-01 • International Journal of Tuberculosis and Lung Disease
2018-04-01 • International Journal of Tuberculosis and Lung Disease
SETTING
The World Health Organization recommended two new drugs, bedaquiline (BDQ) and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in 2013 and 201...
Journal Article
|
Commentary

New opportunities in tuberculosis prevention: implications for people living with HIV

Gonzalez Fernandez L, Casas EDT, Singh SN, Churchyard GJ, Brigden G,  et al.
2020-01-01 • Journal of the International AIDS Society
2020-01-01 • Journal of the International AIDS Society
INTRODUCTION:
Tuberculosis (TB) is a leading cause of mortality among people living with HIV (PLHIV). An invigorated global END TB Strategy seeks to increase efforts in scaling up T...
Journal Article
|
Commentary

A bitter pill to swallow: the need for better medications for drug-resistant tuberculosis in children

Furin J, Mafukidze A, Brigden G, du Cros PAK, Golin R,  et al.
2015-12-01 • International Journal of Tuberculosis and Lung Disease
2015-12-01 • International Journal of Tuberculosis and Lung Disease